- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03308591
Clinical Efficacy of the Neoadjuvant Chemotherapy for IB2 and IIA2 Stage Cervical Cancer Patients
February 1, 2019 updated by: Ding Ma, Huazhong University of Science and Technology
Clinical Efficacy of the Neoadjuvant Chemotherapy for IB2 and IIA2 Stage Cervical Cancer Patients, A Multicenter, Prospective and Randomized Controlled Trial
In recent years, the patients with IB2 and IIA2 stage cervical cancer are still treated with radiotherapy and chemotherapy based treatment, but the radiotherapy will severely damage the function of ovary, cause endocrine dyscrasia and the sexual function of vagina.
So we want to study whether neoadjuvant chemotherapy without radiotherapy will achieve the same outcome compared with traditional therapy including radiotherapy.
So we randomly divide IB2 and IIA2 stage cervical cancer patients into two groups.
The neoadjuvant chemotherapy group will receive two courses of chemotherapy basically composed of platinum, and then undergo surgery, after that, doctors will add more courses of chemotherapy according to the situations of the patients, including whether the patients have the adverse prognostic factors.
The control group will undergo surgery directly, and then receive chemotherapy and radiotherapy at the same time.
Then we will compare the outcomes of these two groups, and analyze the therapeutic effect, the impact on survival rate and the effect on improving the living quality of patient from two groups.
All the outcomes will be fed back to clinical doctors and instruct them to choose better treatment for patients.
Study Overview
Status
Unknown
Intervention / Treatment
Study Type
Interventional
Enrollment (Anticipated)
800
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Ding Ma, MD PhD
Study Locations
-
-
Hubei
-
Wuhan, Hubei, China, 430030
- Recruiting
- Tongji Hospital, Tongji Medical college, Huazhong University of Science and Technology
-
Contact:
- Ding Ma, MD PhD
- Email: dma@tjh.tjmu.edu.cn
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
No older than 65 years (Child, Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
Female
Description
Inclusion Criteria:
- clinical diagnosis IB2 or IIA2 stage cervical cancer;
- age less than or equal to 65 years old;
- laboratory examination results: WBC ≥ 4*10^9/L, NEU ≥ 20*10^9/L, PLT ≥ 80*10^9/L, serum bilirubin ≤ 2 multiples of the upper normal limit, aminopherase ≤ 2 multiples of the upper normal limit. BUN ≤ normal limit, CR ≤ normal limit;
- KARNOFSKY score ≥ 60;
- No prior treatment;
- pathological diagnosis before surgery is invasive squamous cell carcinoma of cervix;
- well-compliance and willing to keep in touch;
- willing to participate in this study, and sign the informed consent;
Exclusion Criteria:
- participate in other drug clinical trials at the same time;
- respiratory depression, airway obstruction and hypoxia;
- heart diseases (cardiac function at grade II, III or above);
- hematological diseases;
- obvious dysfunction of liver and kidney (above 3 multiples of the upper normal limit);
- a history of brain dysfunction;
- unable to receive surgery and/or unsuitable for radiotherapy or chemotherapy;
- drug abuse or a history of drug abuse;
- unable or unwilling to sign informed consents;
- unable or unwilling to follow the protocols;
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: NACT
The patients will receive 2 courses of platinum based chemotherapy before surgery, 2-3 weeks after each course, doctors will appraise the effect of the chemotherapy.
Patients who are sensitive to the treatment will undergo radical hysterectomy and pelvic lymph node dissection 3 weeks after chemotherapy.
And 2-3weeks after the surgery, patients will receive adjuvant chemotherapy according to the pathological risk factors.
|
Platin based chemotherapy
radical hysterectomy+pelvic lymphadenectomy
Platin based chemotherapy
|
Active Comparator: PST
The patients in this group will undergo radical hysterectomy and pelvic lymph node dissection directly, and 2-6 weeks after the surgery, they will receive adjuvant chemotherapy according to the pathological risk factors.
|
radical hysterectomy+pelvic lymphadenectomy
Platin based chemotherapy
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
disease-free survival (DFS) of the neoadjuvant chemotherapy Group
Time Frame: Up to 3-year
|
DFS was definite as the time from randomization to disease recurrence (including death from recurrence if it was the first manifestation of recurrence), death without recurrence.
|
Up to 3-year
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
DSF of the synchro-chemoradiotheraphy group
Time Frame: Up to 3-year
|
Up to 3-year
|
Other Outcome Measures
Outcome Measure |
Time Frame |
---|---|
chemotherapy- and radiotherapy- related adverse effects respectively in two groups
Time Frame: Up to 3-year
|
Up to 3-year
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Study Chair: Ding Ma, MD PhD, Huazhong University of Science and Technology
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
January 1, 2016
Primary Completion (Anticipated)
April 30, 2019
Study Completion (Anticipated)
December 31, 2020
Study Registration Dates
First Submitted
October 8, 2017
First Submitted That Met QC Criteria
October 11, 2017
First Posted (Actual)
October 12, 2017
Study Record Updates
Last Update Posted (Actual)
February 4, 2019
Last Update Submitted That Met QC Criteria
February 1, 2019
Last Verified
February 1, 2019
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CSEM GOG-005B
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Undecided
IPD Plan Description
The individual participants data will be preserved in the hospital, and all the chemical or physical examination results will be kept in the medical records, the researches, ethics committee and the drug administration will be permitted to look up all the records as we planned.
And all the reports or papers about this research will not relate to the patients' identity.
But we do not decide whether the information be available to others, the final decision maybe decided by all the patients in this research.
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cervical Cancer
-
University of California, San DiegoWithdrawnCervical Cancer | Cervical Cancer Stage | Cervical Cancer Stage IB2 | Cervical Cancer Stage IB1 | Cervical Cancer Stage I | Cervical Cancer Stage IB | Cervical Cancer Stage II | Cervical Cancer Stage IIa | Cervical Cancer, Stage IIB | Cervical Cancer, Stage III | Cervical Cancer Stage IIIB | Cervical Cancer... and other conditionsUnited States
-
M.D. Anderson Cancer CenterWithdrawnStage IB3 Cervical Cancer FIGO 2018 | Stage II Cervical Cancer FIGO 2018 | Stage IIA Cervical Cancer FIGO 2018 | Stage IIA1 Cervical Cancer FIGO 2018 | Stage IIA2 Cervical Cancer FIGO 2018 | Stage IIB Cervical Cancer FIGO 2018 | Stage III Cervical Cancer FIGO 2018 | Stage IIIA Cervical Cancer FIGO... and other conditions
-
Abramson Cancer Center of the University of PennsylvaniaWithdrawnCervical Cancer | Stage IB Cervical Cancer | Stage IIA Cervical Cancer | Stage IIB Cervical Cancer | Stage III Cervical Cancer | Stage IVA Cervical Cancer
-
National Cancer Institute (NCI)CompletedCervical Adenocarcinoma | Cervical Squamous Cell Carcinoma | Stage IB Cervical Cancer | Stage IIA Cervical Cancer | Stage IIB Cervical Cancer | Stage III Cervical Cancer | Stage IVA Cervical Cancer | Stage IVB Cervical CancerUnited States
-
Mayo ClinicNational Cancer Institute (NCI)RecruitingCervical Adenosquamous Carcinoma | Cervical Squamous Cell Carcinoma, Not Otherwise Specified | Recurrent Cervical Carcinoma | Stage IB3 Cervical Cancer FIGO 2018 | Stage II Cervical Cancer FIGO 2018 | Stage IIA Cervical Cancer FIGO 2018 | Stage IIA1 Cervical Cancer FIGO 2018 | Stage IIA2 Cervical... and other conditionsUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingStage IA Cervical Cancer | Stage IB Cervical Cancer | Stage IA1 Cervical Cancer | Stage IA2 Cervical Cancer | Stage IB1 Cervical Cancer | Stage IB2 Cervical Cancer | Stage IB3 Cervical CancerUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)CompletedRecurrent Cervical Cancer | Stage IVA Cervical Cancer | Stage IVB Cervical Cancer | Stage IIIA Cervical Cancer | Stage IIIB Cervical CancerUnited States
-
Gynecologic Oncology GroupNational Cancer Institute (NCI)CompletedCervical Adenocarcinoma | Cervical Squamous Cell Carcinoma | Stage IB Cervical Cancer | Stage IIA Cervical Cancer | Stage IIB Cervical Cancer | Stage III Cervical Cancer | Stage IVA Cervical CancerUnited States
-
Shanghai First Maternity and Infant HospitalNot yet recruitingCervical Cancer, Stage IIB | Cervical Cancer Stage IIIB | Cervical Cancer Stage IIIA | Cervical Cancer, Stage IVA
-
Institut de Cancérologie de LorraineCompletedCervical Adenocarcinoma | Stage IB Cervical Cancer | Stage III Cervical Cancer | Stage II Cervical CancerFrance
Clinical Trials on NACT
-
Sun Yat-sen UniversityCompletedNasopharyngeal CarcinomaChina
-
Peking UniversityUnknown
-
Sun Yat-sen UniversityUnknownCervical Carcinoma Stage IIBChina
-
Seoul National University HospitalCompletedBreast CancerKorea, Republic of
-
Peking UniversityBeijing Municipal Science & Technology CommissionUnknown
-
Shu-Zhong CuiXiangya Hospital of Central South University; Wuhan University; Peking University... and other collaboratorsUnknownFallopian Tube Cancer | Epithelial Ovarian Cancer | Primary Peritoneal CarcinomaChina
-
Shanghai Gynecologic Oncology GroupRecruitingFallopian Tube Cancer | Epithelial Ovarian Cancer | Primary Peritoneal CarcinomaKorea, Republic of, China
-
Shanghai Gynecologic Oncology GroupXinhua Hospital, Shanghai Jiao Tong University School of Medicine; Obstetrics... and other collaboratorsNot yet recruitingFallopian Tube Cancer | Epithelial Ovarian Cancer | Primary Peritoneal CarcinomaChina
-
Indrayani Hospital and Cancer InstituteTata Capital Limited; Grant Medical Foundation Ruby hall ClinicCompletedSquamous Cell Carcinoma of Oral CavityIndia
-
AGO Study GroupActive, not recruitingOvarian CancerUnited States, France, Germany, Austria, Sweden, Denmark, Italy, United Kingdom